Antiviral drugs of the category of nucleoside reverse transcriptase inhibitors (NRTIs), largely used for the treatment of HIV infection, can have toxic effects on mitochondria. We performed a cross-sectional study on mitochondrial toxicity in a randomized group of patients belonging to a larger randomized study on different NRTI-based once-daily regimens by quantifying mitochondrial DNA (mtDNA), three different mitochondrial RNAs (mtRNAs) and functional parameters in highly purified peripheral CD4+ and CD8+ T-cells.
Methods
A total of 49 previously treatment-naive patients treated for a mean of 15 months with efavirenz plus didanosine plus lamivudine (group 1), or tenofovir disoproxil fumarate plus lamivudine (group 2), or didanosine plus abacavir (group 3) were considered. The groups were matched for sex, age, CDC classification, risk factor for HIV, nadir CD4+ T-cell count and baseline viral load. mtDNA and mtRNA were quantified by using real-time PCR assays.
Results
No patient showed any clinical symptom; however, the amount of mtDNA in CD4+ and CD8+ T-cells was significantly lower in groups 1 and 3; similarly, the expression of different mtRNAs in both CD4+ and CD8+ T-cells showed significant differences that were dependent upon the drug used. No differences were found in mitochondrial membrane potential and mitochondrial mass in peripheral lymphocytes. The amount of total HIV DNA in CD4+ T-cells did not differ among the groups, who displayed a similar immune reconstitution and control of the virus.
Conclusions
An efficient didanosine-containing once-daily therapy can have more mitochondrial toxicity than regimens devoid of this drug.
References
1.
KakudaT.N.Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.Clin Ther2000; 22: 685–708.
2.
BrinkmanK., SmeitinkJ.A., RomijnJ.A., ReissP.Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.Lancet1999; 354: 1112–1115.
3.
CossarizzaA., MoyleG.Antiretroviral nucleoside and nucleotide analogues and the mitochondria.AIDS2004; 18: 137–151.
4.
MartinJ.L., BrownC.E., Matthews-DavisN., ReardonJ.E.Effects of antiviral nucleoside analogs on human DNA polymerase and mitochondrial DNA synthesis.Antimicrob Agents Chemother1994; 38: 2743–2749.
5.
CôtéH.C., BrummeZ.L., CraibK.J.Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.N Engl J Med2002; 346: 811–820.
6.
McComseyG., TanD.J., LedermanM., WilsonE., WongL.J.Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy.AIDS2002; 16: 513–518.
7.
ShiramizuB., ShikumaK.M., KamemotoL.Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy.J Acquir Immune Defic Syndr2003; 32: 370–374.
8.
HaugaardS.B., AndersenO., PedersenS.B.Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy.J Med Virol2005; 77: 29–38.
9.
SetzerB., SchlesierM., ThomasA.K., WalkerU.A.Mitochondrial toxicity of nucleoside analogues in primary human lymphocytes.Antivir Ther2005; 10: 327–334.
10.
LópezS., CollO., DurbanM.Mitochondrial DNA depletion in oocytes of HIV-infected antiretroviral-treated infertile women.Antivir Ther2008; 13: 833–838.
11.
CossarizzaA.Tests for mitochondrial function and DNA: potentials and pitfalls.Curr Opin Infect Dis2003; 16: 5–10.
12.
MussiniC., PintiM., BugariniR.Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study.AIDS2005; 19: 1627–1633.
13.
BanasB., KostB.P., GoebelF.D.Platelets, a typical source of error in real-time PCR quantification of mitochondrial DNA content in human peripheral blood cells.Eur J Med Res2004; 9: 371–377.
14.
AndersonP.L., KakudaT.N., LichtensteinK.A.The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities.Clin Infect Dis2004; 38: 743–753.
15.
CossarizzaA., PintiM., MorettiL.Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically-infected HIV+ children with HAART-related lipodystrophy.J Infect Dis2002; 185: 299–305.
16.
RossoR., NasiM., Di BiagioA.Effects of the change from stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.Pediatr Infect Dis J2008; 27: 17–21.
17.
GalluzziL., PintiM., TroianoL.Changes in mitochondrial RNA production in cells treated with nucleoside analogues.Antivir Ther2005; 10: 191–195.
18.
GalluzziL., PintiM., GuaraldiG.Altered mitochondrial RNA production in adipocytes from HIV-infected individuals with lipodystrophy.Antivir Ther2005; 10 Suppl 2: M91–M99.
19.
MallonP.W., UnemoriP., SedwellR.In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA.J Infect Dis2005; 191: 1686–1696.
20.
FerraresiR., TroianoL., RossiD.Mitochondrial membrane potential and nucleosidic inhibitors of HIV reverse transcriptase: a cytometric approach.Mitochondrion2004; 4: 271–278.
21.
CaronM., AuclairM., LagathuC.The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro.AIDS2004; 18: 2127–2136.
22.
FerraresiR., TroianoL., RoatE.Protective effect of acetyl-l-carnitine against oxidative stress induced by antiretroviral drugs.FEBS Lett2006; 580: 6612–6616.
23.
SalvioliS., ArdizzoniA., FranceschiC., CossarizzaA.JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis.FEBS Lett1997; 411: 77–82.
24.
TroianoL., FerraresiR., LugliE.Multiparametric analysis of cells with different mitochondrial membrane potential during apoptosis by polychromatic flow cytometry.Nat Protoc2007; 2: 2719–2727.
25.
CossarizzaA., Baccarani-ContriM., KalashnikovaG., FranceschiC.A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolcarbocyanine iodide (JC-1).Biochem Biophys Res Commun1993; 197: 40–45.
26.
Garcia FernandezM., Troianol, Morettil. Early changes in intramitochondrial cardiolipin distribution during apoptosis.Cell Growth Differ2002; 13: 449–455.
27.
TortiC., Quiros-RoldanM.E., CologniG.Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naive to antiretrovirals.Curr HIV Res2008; 6: 43–48.
28.
JohnsonA.A., RayA.S., HanesJ.Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase.J Biol Chem2001; 276: 40847–40857.
29.
WalkerU.A., SetzerB., VenhoffN.Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors.AIDS2002; 16: 2165–2173.
30.
LópezS., NegredoE., GarrabouG.Longitudinal study on mitochondrial effects of didanosine-tenofovir combination.AIDS Res Hum Retroviruses2006; 22: 33–39.
31.
LevyR.J., DeutschmanC.S.Deficient mitochondrial biogenesis in critical illness: cause, effect, or epiphenomenon?Crit Care2007; 11: 158.
32.
ReissP., CasulaM., de RondeA., WeverlingG.J., GoudsmitJ., LangeJ.M.Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors.HIV Med2004; 5: 11–14.
33.
MiuraT., GotoM., HosoyaN.Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy.J Med Virol2003; 70: 497–505.
34.
SaitohA., FentonT., AlveroC., FletcherC.V., SpectorS.A.Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.Antimicrob Agents Chemother2007; 51: 4236–4242.
35.
WalkerU.A., BickelM., Lutke VolksbeckS.I.Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients.J Acquir Immune Defic Syndr2002; 29: 117–121.
36.
NolanD., HammondE., MartinA.Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy.AIDS2003; 17: 1329–1338.
37.
CherryC.L., GahanM.E., McArthurJ.C., LewinS.R., HoyJ.F., WesselinghS.L.Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat.J Acquir Immune Defic Syndr2002; 30: 271–277.
38.
GerschensonM., KimC., BerzinsB.Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.J Antimicrob Chemother2009; 63: 1244–1250.
39.
GiordanoC., SebastianiM., PlazziG.Mitochondrial neurogastrointestinal encephalomyopathy: evidence of mitochondrial DNA depletion in the small intestine.Gastroenterology2006; 130: 893–901.
40.
SebastianiM., GiordanoC., NedianiC.Induction of mitochondrial biogenesis is a maladaptive mechanism in mitochondrial cardiomyopathies.J Am Coll Cardiol2007; 50: 1362–1369.
41.
ZannaC., GhelliA., PorcelliA.M.OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion.Brain2008; 131: 352–367.
42.
FrisardM.I., BroussardA., DaviesS.S.Aging, resting metabolic rate, and oxidative damage: results from the Louisiana Healthy Aging Study.J Gerontol A Biol Sci Med Sci2007; 62: 752–759.
43.
DahmaniY., MarcuelloA., Diez-SanchezC., Ruiz-PesiniE., MontoyaJ., Lopez-PerezM.J.Association of human mitochondrial DNA variants with plasma LDL levels.Mitochondrion2008; 8: 247–253.
44.
LeeH.K., SongJ.H., ShinC.S.Decreased mitochondrial DNA content in peripheral blood precedes the development of non-insulin-dependent diabetes mellitus.Diabetes Res Clin Pract1998; 42: 161–167.
45.
ParkK.S., LeeK.U., SongJ.H.Peripheral blood mitochondrial DNA content is inversely correlated with insulin secretion during hyperglycemic clamp studies in healthy young men.Diabetes Res Clin Pract2001; 52: 97–102.
46.
LimS., ParkK.S., KimM.S., ChoB.Y., LeeH.K.Relationship between various surrogate indices of insulin resistance and mitochondrial DNA content in the peripheral blood of 18 healthy volunteers.Mitochondrion2001; 1: 71–77.
47.
LimS., KimM.S., ParkK.S.Correlation of plasma homocysteine and mitochondrial DNA content in peripheral blood in healthy women.Atherosclerosis2001; 158: 399–405.
48.
StoccoD.M.StAR protein and the regulation of steroid hormone biosynthesis.Annu Rev Physiol2001; 63: 193–213.
49.
YaoP.M., TabasI.Free cholesterol loading of macrophages is associated with widespread mitochondrial dysfunction and activation of the mitochondrial apoptosis pathway.J Biol Chem2001; 276: 42468–42476.
50.
CossarizzaA., RivaA., PintiM.Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy.Antivir Ther2003; 8: 315–321.
